27 January 2021 - NICE has completed its review of trifluridine with tipiracil hydrochloride for the treatment of patients with metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma.

Trifluridine with tipiracil hydrochloride is not recommended, within its marketing authorisation, for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma in adults who have had two or more systemic treatment regimens.

The most plausible cost effectiveness estimate is much higher than what NICE normally considers an acceptable use of NHS resources.

Read NICE technology appraisal guidance for trifluridine with tipiracil hydrochloride